• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Genocea Biosciences Inc. (Amendment)

    2/14/22 4:09:41 PM ET
    $GNCA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNCA alert in real time by email
    SC 13G/A 1 genocea_13gam1dec312021.htm SC 13G/A



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Genocea Biosciences, Inc.

     
    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

     
    (Title of Class of Securities)

     

    372427401

     
    (CUSIP Number)

     

     

    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     
     

     

     

    CUSIP No.  372427401  SCHEDULE 13G  

     

             
    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    3,079,756*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    3,079,756*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,079,756*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4%

    12

    TYPE OF REPORTING PERSON

     

    IA

    *See Item 4 for additional information.

     


     
     

     

     

    CUSIP No.  372427401  SCHEDULE 13G  

     

             
    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital Master LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    3,079,756*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    3,079,756*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,079,756*

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4%

    12

    TYPE OF REPORTING PERSON

     

    OO

    *See Item 4 for additional information.

     

     

     
     

     

     

     

    CUSIP No. 372427401  SCHEDULE 13G  

     

    Item 1.   (a) Name of Issuer

    Genocea Biosciences, Inc. (the “Issuer”)

     

    Item 1.   (b) Address of Issuer’s Principal Executive Offices

    100 Acorn Park Drive, Cambridge, Massachusetts 02140

     

    Item 2.   (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:

    This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 767 Fifth Avenue, Floor 12, New York, NY 10153.

      

    Item 2.   (d) Title of Class of Securities

    Common Stock, $0.001 par value per share (the “Common Stock”)

     

    Item 2.   (e) CUSIP No.:

    372427401

     

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:

     

    N/A

     

     

     
     

     

     

    CUSIP No. 372427401  SCHEDULE 13G  

     

     

    Item 4. Ownership

     

    Information with respect to the Firm’s ownership of securities of the issuer is incorporated by reference to items (5) - (9) and (11) of the respective cover page of the Firm.

    As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:

    (a) Amount Beneficially Owned: 3,079,756*

    (b) Percent of Class: 5.4%*

    (c) Number of Shares as to which such person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 3,079,756*

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 3,079,756*

     

    As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:

    (a) Amount Beneficially Owned: 3,079,756*

    (b) Percent of Class: 5.4%*

    (c) Number of Shares as to which such person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 3,079,756*

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 3,079,756*

     

    *The Firm is the investment manager to Commodore Master. As of December 31, 2021, the Firm may be deemed to beneficially own an aggregate of 3,079,756 shares of Common Stock of the Issuer. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 57,445,391 shares of Common Stock reported as issued and outstanding in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on October 28, 2021.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

     
     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Exhibit Index

     

    1.Joint Filing Agreement dated as of March 31, 2021, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on March 31, 2021).

     

     

     
     

     

     

    CUSIP No. 372427401  SCHEDULE 13G  

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

     

    Commodore Capital LP

     

    By: /s/ Michael Kramarz

    Michael Kramarz, Managing Partner

     

     

    Commodore Capital Master LP

     

    By: /s/ Michael Kramarz

    Michael Kramarz, Authorized Signatory

     

     

     

     

     

     

    Get the next $GNCA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNCA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNCA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SVB Leerink reiterated coverage on Genocea Biosciences with a new price target

      SVB Leerink reiterated coverage of Genocea Biosciences with a rating of Outperform and set a new price target of $6.00 from $5.00 previously

      4/6/21 7:42:43 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Genocea Biosciences with a new price target

      Needham reiterated coverage of Genocea Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously

      2/11/21 11:14:26 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNCA
    Financials

    Live finance-specific insights

    See more
    • Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast

      CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 1066689. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will

      3/3/22 8:00:00 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genocea Provides Third Quarter 2021 Corporate Update

      GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the third quarter ended September 30, 2021. "We continue to make significant progress. Most notably, we are very excited about our TiTAN™ clinical trial for GEN-011, our neoantigen-targeted peripheral T cell therapy (NPT) candidate, from which we expect to have initial data from a small subset of patient

      10/28/21 7:00:00 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genocea to Host Third Quarter 2021 Corporate Update Conference Call & Webcast

      CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2021 corporate update conference call and live audio webcast on Thursday, October 28th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 8729366. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will be available on the Genocea we

      10/21/21 4:30:00 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Duvall Diantha sold $81 worth of shares (1,355 units at $0.06), decreasing direct ownership by 2% to 75,388 units to satisfy tax liability

      4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)

      6/3/22 4:13:21 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Flechtner Jessica Baker sold $95 worth of shares (1,578 units at $0.06), decreasing direct ownership by 2% to 89,027 units (withholding obligation)

      4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)

      6/3/22 4:12:24 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Clark William D sold $241 worth of shares (4,023 units at $0.06), decreasing direct ownership by 1% to 304,377 units to satisfy withholding tax

      4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)

      6/3/22 4:11:27 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNCA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genocea Announces Wind Down of Operations and Delisting From NASDAQ

      CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company's ongoing operations and terminate the Company's remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the Nasdaq Capital Market in connection with the wind down of its operations. The Company plans to file a Form 25 with the Securities and Exchange Commission on or about June 2

      5/24/22 8:00:00 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

      CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company, merger or reverse merger. As we pursue strategic alternatives, the Company has put into place a restructuring plan which includes an approximate 65% reduction in workforce in the second q

      4/28/22 4:05:10 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022

          GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward potentially more effective regimen Initial translational data corroborate clinical findings PLANETTM manufacturing process is highly reliable and continues to improve; patients next to be dosed to receive GEN-011 with substantially boosted yields, neoantigen specificity and potency Investor webcast at 4:30 pm ET today to further discuss data CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation n

      4/8/22 1:05:00 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNCA
    SEC Filings

    See more
    • SEC Form 15-12B filed by Genocea Biosciences Inc.

      15-12B - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)

      6/13/22 5:21:30 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Genocea Biosciences Inc.

      EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)

      6/13/22 12:15:11 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Genocea Biosciences Inc.

      EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)

      6/13/22 12:15:07 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNCA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Genocea Biosciences Inc. (Amendment)

      SC 13D/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)

      5/27/22 4:34:16 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Genocea Biosciences Inc. (Amendment)

      SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)

      2/14/22 4:09:41 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Genocea Biosciences Inc. (Amendment)

      SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)

      2/14/22 6:19:47 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care